Medivir

Medivir Net Debt / EBITDA

The Net Debt to EBITDA of Medivir (MVIR.ST) as of Nov 22, 2026 is 1.39. In the previous year, Net Debt to EBITDA was 0.72 — a change of 93.39% (higher).

Net Debt / EBITDA

1.39

YoY

93.39%

Last updated:

Net Debt to EBITDA of Medivir is 2020 1.39 . Net Debt to EBITDA of Medivir was 2019 0.72 . It decreases by 93.39% higher compared to the previous year.

The Medivir Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2012
-0.05 SEK
Jan 1, 2013
1.92 SEK
Jan 1, 2014
-1.14 SEK
Jan 1, 2016
5.44 SEK
Jan 1, 2017
1.29 SEK
Jan 1, 2018
0.82 SEK
Jan 1, 2019
0.72 SEK
Jan 1, 2020
1.39 SEK
The Medivir Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.39+93.39%
0.72-11.79%
0.82-36.74%
1.29-76.29%
5.44-576.79%
-1.14-159.33%
1.92-3,881.37%
-0.05-154.41%
0.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Net Debt to EBITDA of Medivir is 1.39 in 2020.

Net Debt to EBITDA of Medivir changed from 0.72 to 1.39, representing a 93.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Medivir since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Medivir with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medivir

All Key Metrics — Medivir